



Title	Zika virus infection—the next wave after dengue?
Author(s)	Wong, SSY; Poon, RWS; Wong, SCY
Citation	Journal of the Formosan Medical Association, 2016, v. 115 n. 4, p. 226-242
Issued Date	2016
URL	http://hdl.handle.net/10722/231181
Rights	This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.



Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.jfma-online.com



REVIEW ARTICLE

Zika virus infection—the next wave after dengue?



Samson Sai-Yin Wong^{a,*}, Rosana Wing-Shan Poon^b,
Sally Cheuk-Ying Wong^b

^a Department of Microbiology, Research Centre for Infection and Immunology, Faculty of Medicine, The University of Hong Kong, Hong Kong

^b Department of Microbiology, Queen Mary Hospital, Hong Kong

Received 16 February 2016; accepted 17 February 2016

KEYWORDS

Zika virus;
Flavivirus;
Aedes;
travel medicine;
congenital
abnormalities

Zika virus was initially discovered in east Africa about 70 years ago and remained a neglected arboviral disease in Africa and Southeast Asia. The virus first came into the limelight in 2007 when it caused an outbreak in Micronesia. In the ensuing decade, it spread widely in other Pacific islands, after which its incursion into Brazil in 2015 led to a widespread epidemic in Latin America. In most infected patients the disease is relatively benign. Serious complications include Guillain–Barré syndrome and congenital infection which may lead to microcephaly and maculopathy. *Aedes* mosquitoes are the main vectors, in particular, *Ae. aegypti*. *Ae. albopictus* is another potential vector. Since the competent mosquito vectors are highly prevalent in most tropical and subtropical countries, introduction of the virus to these areas could readily result in endemic transmission of the disease. The priorities of control include reinforcing education of travellers to and residents of endemic areas, preventing further local transmission by vectors, and an integrated vector management programme. The container habitats of *Ae. aegypti* and *Ae. albopictus* means engagement of the community and citizens is of utmost importance to the success of vector control.

Copyright © 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Conflict of interest: The authors have no conflicts of interest relevant to this article.

* Corresponding author. Department of Microbiology, LG-1 Block K, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong. Tel.: +852 2255 3206.

E-mail address: samsonsy@hku.hk (S.S.-Y. Wong).

<http://dx.doi.org/10.1016/j.jfma.2016.02.002>

0929-6646/Copyright © 2016, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

The past decades have seen some hitherto exotic arboviruses and other arthropod-borne infections emerging from oblivion into epidemic diseases of global concern. The burden of dengue has been rising for five decades.¹ The 2004–2005 outbreak of chikungunya in East Africa and Indian Ocean was followed by worldwide spread in both the Old and New Worlds in the ensuing decade.² The expanding geographical distribution of these arboviral diseases is further fuelled by climate changes and importation of invasive arthropod species (most notably various *Aedes* mosquitoes such as *Ae. albopictus*, *Ae. japonicus*, *Ae. aegypti*, and *Ae. koreicus*) into temperate countries of Europe and North America.^{3,4} The consequences of climate change and vector distribution can be seen in the autochthonous transmission of dengue and chikungunya in high-latitude areas such as Japan and European countries.^{5,6} Zika virus is the latest culprit in a long list of arbovirus epidemics that emerged in the past two decades. As a largely neglected disease, little is known about the basic biology of the virus and the disease until the past decade when it made its mark outside Africa, not to mention vaccine development and antiviral studies. At the time of writing (early 2016), the epidemic in Latin America is still evolving. As in the case of other emerging epidemics such as chikungunya, new clinical and laboratory features may be recognized which may impact on future management of the disease. We herewith summarized what is currently known about the infection, highlighted the uncertainties, and examined the approaches to prevention and control of similar arthropod-borne infections which are pertinent to areas with risks of disease introduction and transmission.

Virology

The family *Flaviviridae* contains some of the most clinically important arboviruses (Table 1). The prototype agent, yellow fever virus, is indeed the first human virus discovered and found to be transmitted by an arthropod vector.^{7,8} There are currently four genera in *Flaviviridae*, *Flavivirus* (53 species), *Hepacivirus* (one species, the hepatitis C virus), *Pegivirus* (two species), and *Pestivirus* (four species).⁹ With the exception of the hepatitis C virus, most of

the clinically relevant pathogens belong to the genus *Flavivirus*. Epidemiologically, the arthropod-borne flaviviruses can be divided into mosquito-borne and tick-borne viruses. Flaviviruses with no known vectors are also found in animals. Clinically, the most prominent syndromes caused by flaviviruses are undifferentiated febrile illnesses (often presenting as a fever with rash syndrome), central nervous system infection (especially encephalitis), visceral involvement, and haemorrhagic fever.

Flaviviruses are enveloped, single-stranded, positive sense RNA viruses measuring about 50 nm in size. The viral genome is about 10.5 to 11 kbp in size.^{12,13} The viral genome produces a polyprotein with more than 3000 amino acids; this polyprotein is then cleaved into three structural and seven non-structural proteins.¹⁰ The flaviviral genome encodes (from 5' to 3' end, i.e. from N- to C-terminal of the polyprotein) the structural C (capsid, ~11 kDa), prM (precursor M protein, ~26 kDa, which is further cleaved into the M protein), and E (envelope, ~53 kDa) proteins, and the non-structural NS1 (~46 kDa), NS2A (~22 kDa), NS2B (~14 kDa), NS3 (~70 kDa), NS4A (~16 kDa), NS4B (~27 kDa), and NS5 (~103 kDa) proteins.¹⁰ Structurally, the E and M proteins are located at the surface of the viral particles, while the nucleocapsid is made up of the C protein and the genomic RNA molecule.

Table 2 summarizes the key functions and host effects of the flaviviral proteins. It must be remembered that the current knowledge on the effects of various viral proteins on host immune system and pathogenesis is based on previous studies on clinically important flaviviruses such as dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus. Whether the findings can be generalized to other flaviviruses including Zika virus is unknown.

Initial isolation of Zika virus was made from a sentinel rhesus monkey in 1947 in the Zika Forest area of the Entebbe Peninsula in Uganda on the northwestern shore of Lake Victoria.²⁸ In 1948, the virus was also detected in a batch of *Aedes africanus* mosquitoes.²⁸ Isolation of the virus from humans were then reported in Uganda, Tanzania, and Nigeria in the 1950s.^{29,30} The genomes of the three human isolates of Zika virus are 10,676 bp in size, which is comparable to other members of *Flaviviridae*.³¹ Zika virus is phylogenetically closest to the Spondweni virus, which is

Table 1 Key clinical and epidemiological features of important flaviviruses causing human infections.^{10,11}

Main clinical syndrome ^a	Vectors	
	Mosquito-borne	Tick-borne
Central nervous system infection	Japanese encephalitis virus, Murray Valley encephalitis virus, Ntaya virus, Rocio virus, St. Louis encephalitis virus, Usutu virus, West Nile virus	Louping ill virus, Powassan virus, tick-borne encephalitis virus
Viscerotropic infections ± haemorrhagic fever	Yellow fever virus, dengue virus	Alkhurma virus, Kyasanur Forest disease virus, Omsk haemorrhagic fever virus
Febrile illnesses	Dengue virus, Ilheus virus, Kokobera virus, Spondweni virus, Zika virus	

^a Overlaps in the clinical syndromes do occur for individual viruses.

Table 2 Key proteins of flaviviruses and their functions.^{10,14–27}

Proteins	Functions	Possible effects on hosts
C	RNA binding to form the nucleocapsid.	
prM, M	Stabilization, assisting the folding and secretion of E protein.	Antibodies towards prM enhances infectivity of immature virions, could be involved in pathogenesis of severe dengue in secondary infections.
E	Receptor binding, membrane fusion.	
NS1	RNA replication.	Localization to host cell surface and secreted extracellularly; modulates signalling of innate immune system, possible damages to platelets and endothelial cells through anti-NS1 antibodies, antagonizes C4 complement.
NS2A	RNA synthesis and viral assembly.	Interferon antagonist, induces host cell apoptosis.
NS2B	Complexes with NS3 to function as serine protease.	
NS3	Complexes with NS2B to function as serine protease; possess RNA helicase and triphosphatase activities.	Induces apoptosis of host cells, modulates host microRNA, one of the targets of cytotoxic T cell response.
NS4A	RNA replication.	Blocks type I interferon signalling, induces autophagy and protects host cells from death during infection.
NS4B	RNA replication.	Blocks type I interferon signalling and RNA interference, modulator of stress granules in host cells.
NS5	Methyltransferase and RNA guanylyltransferase activities; capping and synthesis of RNA; RNA-dependent RNA polymerase.	Blocks type I interferon signalling.

also a mosquito-borne flavivirus that has been found to cause a febrile illness in Africa.³²

Several flaviviruses are noted for their propensity to cause central nervous system infections, in particular, encephalitis (Table 1). Globally, Japanese encephalitis virus, Murray Valley encephalitis virus, St. Louis encephalitis virus, West Nile virus, and tick-borne encephalitis (and to some extent, dengue virus, though neurological involvement is generally not a common feature of dengue) are the most commonly encountered pathogens in this regard.³³ In addition to the wild-type viruses, even apparently attenuated vaccine strains may still possess some degree of neurovirulence, as demonstrated by the yellow fever 17D vaccine.³⁴ The exact genetic determinants of flaviviral neurovirulence have not been completely elucidated, though it appears to be related to multiple genes such as E, NS1, NS3, and NS5.^{33,35–41} This area is particularly relevant to Zika virus infection which was previously considered to be a relatively harmless febrile illness with low case-fatality ratio, but microcephaly has emerged as a unique potential sequel of the infection in pregnant women during the Latin American epidemic that began in 2015. Although the exact causality, risk, and mechanism between the infection and microcephaly remain to be investigated, a recent report described the presence of Zika virus in the brain tissues of an affected foetus as demonstrated by both reverse transcription polymerase chain reaction (RT-PCR) and electron microscopy.⁴²

The phylogenetic relationships of flaviviruses have been well studied.^{12,13,43} Phylogeny is most commonly studied by NS5 sequences, but the NS3 and E sequences or the entire coding region have also been utilized for studies. In general, clustering of flaviviruses can be seen in phylogenetic trees based on the type of transmission vectors (mosquitoes [*Aedes* versus *Culex*], ticks, or no known vectors), type of clinical syndromes (encephalitic versus non-encephalitic

diseases), and geographical distribution of the viruses.¹² Figure 1 shows the phylogenetic relationship of the clinically relevant flaviviruses found in humans. As expected, phylogenetic trees based on NS5 and E sequences showed a clear clustering of the mosquito-borne versus tick-borne viruses, and viruses that cause central nervous system infections are also clustered together. Although Zika virus does possess neuropathogenic potentials, at least in the immature nervous system, it is not particularly closely related to other encephalitic viruses. It might be noted that the other potential serious complication of Zika virus infection, Guillain-Barré syndrome (*vide infra*), also affects the nervous system, albeit probably via a different pathogenic mechanism. Moreover, in infants with congenital infection, abnormalities of the retina (which is essentially a part of the central nervous system) were also detected (*vide infra*). Whether the phylogeny explains why Zika virus is not highly neurovirulent in adults but causes substantial damage to the immature neural tissues and possibly induces immunopathological damage in the adult nervous system remains to be studied. Another question begging for an answer is whether both lineages of Zika virus are equally neurovirulent for the foetal brain. This is relevant because the Yap 2007 strain and the Senegal 1984 strain of Zika virus differ from the prototype Uganda strain in that the latter has a four amino acid deletion in the E protein.⁴⁴ Microcephaly has not been reported previously in Africa where the disease is endemic (although the possibility of under-reporting cannot be excluded). Whether the difference in the four amino acids or other genetic changes is associated with virulence or transmissibility is currently unknown. Figure 1 also shows a clear separation of Zika viruses into the African and Asian lineages.⁴⁵ It has been suggested that Zika virus originated in east Africa near Uganda, which subsequently spread to west Africa and central Africa (the African lineage).⁴⁶ The Uganda strain also spread to




Figure 1 Phylogenetic trees showing the relationships between important flaviviruses causing human infection. A total of 1,536 nucleotide positions in envelope (*E*) gene (Figure 1A), 1,067 nucleotide positions in non-structural protein 1 (*NS1*) (Figure 1B), 1,925 nucleotide positions in non-structural protein 3 (*NS3*) (Figure 1C), 2,736 nucleotide positions in non-structural protein 5 (*NS5*) genes (Figure 1D) were included in the analysis. The trees were constructed using the neighbour-joining method. The bootstrap values calculated from 1,000 trees are shown when they are $\geq 70\%$. The scale bar indicates the estimated number of substitutions per 20 bases in *E* and *NS3* and per 50 bases in *NS1* and *NS5*. The names and accession numbers (in parentheses) are presented as cited in the GenBank database. * Mosquito-borne neurotropic viruses; † tick-borne neurotropic viruses; ‡ tick-borne haemorrhagic fever viruses.




Figure 1 (continued).

Table 3 Outbreaks of human Zika virus infection since 2007.^{59–63}

Year	Location	Estimated number of cases	Notable features
2007	Yap Island, Micronesia	49 confirmed, 59 probable, and 72 suspected cases in one study. Estimated over 900 clinical cases, 73% of population infected in 4 months.	<i>Aedes hensilli</i> implicated as the main vector.
2007	Gabon	Detected in 5 archived human samples; total number of cases unknown.	Retrospective study of a concurrent outbreak of dengue and chikungunya; detection of virus in patient sera and <i>Ae. albopictus</i> pools.
2013–2014	French Polynesia	8,723 suspected cases, over 30,000 sought medical care.	Derived from the Asian lineage, closely related to Cambodia 2010 and Yap state 2007 strains. Association with Guillain-Barré syndrome and other neurological complications suspected.
2014	The Cook Islands	932 suspected, 50 confirmed cases.	
2014	New Caledonia	1400 confirmed cases (35 imported).	
2014	Easter Island	51 confirmed out of 89 suspected cases from Jan – May 2014.	Infecting strain closely related to viral strain found in French Polynesia.
2015	Latin America ^a	Estimated 1.5 million cases in Brazil.	Association with microcephaly and maculopathy suspected.

^a As of 10 February 2016. Includes Barbados, Bolivia, Colombia, Commonwealth of Puerto Rico, Costa Rica, Curacao, Dominican Republic, Ecuador, El Salvador, French Guiana, Guadeloupe, Guatemala, Guyana, Haiti, Honduras, Jamaica, Martinique, Mexico, Nicaragua, Panama, Paraguay, Saint Martin, Suriname, U.S. Virgin Islands, Venezuela.

Malaysia and the Micronesia, thereby establishing the Asian lineage. The Yap outbreak in 2007, French Polynesian outbreak in 2013–2014, and the Latin American epidemic since 2015 were due to viruses belonging to the Asian lineage, probably originating from a strain from Southeast Asia.^{44,45,47}

The pathogenesis of Zika virus infection in humans is poorly understood, though studies are starting to unravel the disease process. In a study on the effects of Zika virus, human skin cells, the fibroblasts, keratinocytes, and dendritic cells are all permissive to infection with replication of the virus.⁴⁸ Molecules such as DC-SIGN, AXL, Tyro3, and TIM-1 are involved in cell entry, and both type I and type II interferons inhibit viral multiplication. The utilization of multiple cellular receptors for entry is similar to dengue virus. Another study described the cytokine profiles of six travellers who acquired Zika virus infection in Southeast Asia, French Polynesia, and Latin America.⁴⁹ Significant elevation of multiple cytokines (including interleukins 1b, 2, 4, 6, 9, 10, 13, 17, and IP-10) was observed during acute infection, but not interferon-gamma or tumour necrosis factor-alpha, suggesting a cytokine response towards Th2 reaction. Interleukins 1b, 6, 8, 10, 13, IP-10, RANTES, MIP-1a, MIP-1b, VEGF, FGF, and GM-CSF were elevated during the convalescent phase. The “cytokine storm” which occurs in some other viral infections was not demonstrated in the small cohort of subjects.

Epidemiology and transmission

Since its initial discovery, early virological and serological studies from the 1950s to 1980s showed that Zika virus infection is predominantly limited to African and Asian countries.⁵⁰ In Asia, endemic circulation of the virus (clinical disease and/or seroprevalence studies) has been reported in Indonesia, Cambodia, Thailand, The Philippines, Peninsular Malaysia, and Borneo, and among travellers

returning from endemic areas.^{51–58} The first major epidemic outside Africa occurred in Yap Island of the Federated States of Micronesia (in the western Pacific Ocean, north to Papua New Guinea) in 2007 (Table 3). Since then, Zika, dengue, and chikungunya viruses became rampant in the Pacific islands.⁶¹ Another major epidemic occurred in the western Pacific islands of French Polynesia and New Caledonia in 2013–2014.⁶⁴

The outbreak in Easter Island in 2014 heralded the incursion of the virus to mainland Latin America.⁶² Since early 2015, Brazil reported the first autochthonous case in the city of Natal and this was quickly followed by another large epidemic in Brazil and neighbouring countries in Latin America.^{63,65–68} As of 12 February 2016, there were over 2,000 confirmed and over 118,000 suspected cases in the Americas.⁶⁹ The exact time and route of spread of the virus to Brazil is unknown, but importation during the 2014 World Cup has been postulated.⁶⁵

The virus is epizootic and enzootic in non-human primates in Africa (sylvatic cycle), and these mammals are the most important natural reservoir hosts.⁷⁰ However, as in the case of other arboviruses such as dengue and yellow fever, urban cycles involving human–mosquito–human transmission can readily occur when there are competent anthropophilic vectors. *Aedes* mosquitoes are the primary vectors for natural transmission of the Zika virus. The extrinsic incubation period of the virus in mosquitoes is about 10 days (similar to the 8–12 days required of dengue virus).^{50,71} In *Ae. aegypti*, high levels of viruses could be found within the mosquitoes from days 20–60 after infection, though the average lifespan of female *Ae. aegypti* adults is shorter than this in the tropical field conditions.^{71,72} Species from which the virus has been isolated or found to be capable of transmitting the virus include *Ae. africanus* (chiefly a forest-dwelling mosquito feeding on non-human primates), *Ae. apicoargenteus* (an African mosquito species), *Ae. luteocephalus* (an African mosquito species), *Ae. furcifer* (an African mosquito species), *Ae.*

vittatus (worldwide distribution), *Ae. unilineatus* (found in Africa and parts of Asia, including India, Pakistan, and Saudi Arabia), *Ae. opok* (an African mosquito species described in Uganda), *Ae. hensilli* (endemic species in Micronesia, implicated in the outbreaks of dengue, chikungunya, and Zika virus infections in Yap Island of Micronesia), *Ae. aegypti*, and *Ae. albopictus*.^{59,60,73–79} To most countries of the world, the last two species, *Ae. aegypti* and *Ae. albopictus* (nowadays more properly known as *Stegomyia aegypti* and *Stegomyia albopicta* respectively),⁸⁰ may pose the greatest threats, given their almost ubiquitous presence in many tropical and subtropical countries, their adaptation to the urban and peri-domestic environments, their highly anthropophilic behaviours, invasion into some European and North American countries, and competence to act as vectors for numerous other arboviruses.⁸¹ *Ae. aegypti*, in particular, is considered to be the prime vector for the transmission of Zika virus among humans. *Ae. aegypti* and *Ae. polynesiensis* are suspected to be the vectors involved in the French Polynesian outbreak.^{82,83} In addition, Zika virus has also been isolated from other non-*Aedes* genera of mosquitoes including *Mansonia uniformis*, *Culex perfuscus*, and *Anopheles coustani*.⁸⁴ However, it must be remembered that the ability to isolate the virus from certain mosquito species and their *in vitro* competence to support viral replication does not mean that those species are necessarily important vectors epidemiologically. As in the case of other vectorborne infections, the vectorial capacity depends not only on vector competence, but also on the local density of the vectors, their host biting preference, feeding frequency, longevity (which is relevant to the extrinsic incubation period of the arbovirus), and level of viral replication in the vectors.^{85–87}

In addition to mosquitoes, other routes of transmission of Zika virus are possible, although these are unlikely to be of major epidemiological significance under natural circumstances. Direct transmission from primates to human via animal bites has been suggested though not proven.⁸⁸ Coincidentally, Zika virus has also been detected in the saliva of 19.2% of infected individuals but the epidemiological significance of this remains to be determined.⁸⁹ Sexual transmission has been documented, and the virus has been detected in the semen up to 62 days after onset of febrile illness.^{90–92} Likewise, perinatal and congenital infections can occur.^{42,93} Another major clinical and public health concern is the potential for transmission through transfusion and transplantation. In endemic countries, the proportion of asymptomatic or subclinical flaviviral infections far exceeds the clinically overt cases. For example, the ratios between asymptomatic or inapparent to clinical cases of dengue, Japanese encephalitis, and yellow fever are 3–18:1, 250:1, and 7–12:1 respectively.^{94–96} Detection of arboviruses in donated blood and their transmission through transfusion have been well documented for arboviruses such as dengue, West Nile, and tick-borne encephalitis viruses, with concerns over other viruses such as chikungunya and Ross River viruses.^{97–103} During the French Polynesian Zika outbreak in 2013–2014, 3% of asymptomatic blood donors were found to be viraemic using RT-PCR screening, thereby underscoring the potential for transfusion transmission of Zika virus.¹⁰⁴

Clinical and laboratory aspects

Clinically, Zika virus infection cannot be reliably differentiated from other arbovirus infections such as dengue and chikungunya as the symptoms and signs are not pathognomonic. The clinical and epidemiological features are also confounded by co-circulation of different arboviruses in the same geographical area.⁶⁰ Table 4 compares some of the features of dengue, Zika, and chikungunya. After an incubation period of 3 to 12 days, Zika virus infection presents initially with headache, a descending maculopapular rash involving palms and soles (which can be pruritic), fever, malaise, myalgia, anorexia, conjunctivitis, arthralgia, limb oedema and sometimes abdominal symptoms (abdominal pain, diarrhoea).^{50,105} Limb oedema and conjunctivitis appeared to be commoner with Zika virus infections than dengue or chikungunya, while hepatomegaly, leukopenia, and thrombocytopenia were less common in Zika virus infections.¹⁰⁵ During the Yap outbreak, the main clinical manifestation (incidence in parentheses) were maculopapular rash (90%), fever (65%), arthritis/arthralgia (65%), conjunctivitis (55%), myalgia (48%), headache (45%), retro-orbital pain (39%), oedema (19%), and vomiting (10%).⁵⁹ Serious complications due to Zika virus infection were rarely reported in the past. However, during the French Polynesian outbreak, an increased incidence of Guillain-Barré syndrome was noted, with an incidence that is 20 times higher during the outbreak than non-outbreak periods.^{83,115} An association with Guillain-Barré syndrome was also noted in the Latin American epidemic since 2015. In Brazil, 62% of the Guillain-Barré syndrome patients during the outbreak had preceding symptoms consistent with Zika virus infection.⁶³ Death from Zika virus infection in adults is rare but has been reported, although the exact contribution of the infection to mortality has not been detailed at the moment.¹¹⁶ The duration of immunity after recovery from Zika virus infection is unknown. Co-infection with other arboviruses is possible, since the key *Aedes* vectors are capable of transmitting other arboviruses.¹¹⁷

The most striking and unexpected sequel of Zika virus infection is the possible association with congenital abnormalities, in particular, microcephaly. In some cases, intrauterine or neonatal death may ensue.¹¹⁶ The epidemiological linkage was first observed in Brazil in 2015, where the number of infants born with microcephaly increased 20 times after the onset of the epidemic, with over 1200 cases being reported in 2015 (99.7 per 100,000 livebirths).¹¹⁸ As of 30 January 2016, there were 4,783 cases of congenital central nervous system malformations recorded in Brazil (compared to an annual incidence of 163 microcephaly cases in 2001–2014) with 76 deaths.⁶³ In addition to microcephaly, affected fetuses and infants also have cerebral calcification seen in imaging.^{119,120} In microcephalic infants, retinal abnormalities manifesting as macular neuroretinal atrophy, macular pigment mottling, foveal reflex loss, and chorioretinal atrophy, as well as optic nerve hypoplasia were also observed.^{118,120} Ophthalmological examination of the infected mothers was uniformly normal.

The management of pregnant women with Zika virus infection remains problematic. The main difficulties

Table 4 Epidemiological and clinical features of dengue, Zika, and chikungunya virus infections.^{59,61,105–114}

	Dengue virus	Zika virus	Chikungunya virus
<i>Virology</i>			
Family	<i>Flaviviridae</i>	<i>Flaviviridae</i>	<i>Togaviridae</i>
Nucleic acid	Single-strand, positive sense, RNA.	Single-strand, positive sense, RNA.	Single-strand, positive sense, RNA.
Main divisions	4 serotypes (1 to 4)	2 lineages (African and Asian)	4 major lineages (West African, East/Central/South African [ECSA], Indian Ocean, Asian)
<i>Epidemiology</i>			
Natural reservoir	Primates (sylvatic cycle).	Primates (sylvatic cycle).	Primates (sylvatic cycle).
Key vectors for natural transmission	<i>Aedes</i> mosquitoes. Sylvatic cycle: <i>Ae. furcifer</i> , <i>Ae. luteocephalus</i> , <i>Ae. vittatus</i> , <i>Ae. taylori</i> , <i>Ae. niveus</i> . Urban cycle: <i>Ae. aegypti</i> and <i>Ae. albopictus</i> , other locally predominant species implicated (e.g. <i>Ae. polynesiensis</i> , <i>Ae. pseudoscutellaris</i> , <i>Ae. malayensis</i> , <i>Ae. cooki</i>).	<i>Aedes</i> mosquitoes. Sylvatic cycle: <i>Ae. africanus</i> , <i>Ae. furcifer</i> , <i>Ae. luteocephalus</i> , <i>Ae. vittatus</i> , <i>Ae. unilineatus</i> , <i>Ae. opok</i> . Urban cycle: <i>Ae. aegypti</i> , <i>Ae. albopictus</i> ; other locally predominant species implicated (e.g. <i>Ae. hensilli</i> , <i>Ae. polynesiensis</i>).	<i>Aedes</i> mosquitoes. Sylvatic cycle: <i>Ae. africanus</i> , <i>Ae. furcifer</i> , <i>Ae. luteocephalus</i> , <i>Ae. neoafricanus</i> , <i>Ae. taylori</i> , <i>Ae. dalzieli</i> , <i>Ae. vigilax</i> , <i>Ae. camptorhynchites</i> , <i>Ae. fulgens</i> . Possibly <i>Mansonia</i> spp. as well. Urban cycle: <i>Ae. aegypti</i> , <i>Ae. albopictus</i> .
Endemic areas	Tropics and subtropic areas. Widespread in Asia, Africa, Latin America, Pacific islands, northeast Australia. Increasing cases reported in southwestern and southeastern United States. ^a	<i>Asia</i> : Cambodia, Indonesia, Malaysia, Pakistan, The Philippines, Thailand. <i>Pacific islands</i> : Micronesia, French Polynesia, New Caledonia, The Cook Islands. <i>Africa</i> : Senegal, Uganda, Nigeria, Côte d'Ivoire, Gabon, Tanzania, Egypt, Central African Republic, Sierra Leone. <i>Latin America</i> : since 2015. ^b	Widespread in sub-Saharan Africa, Asia, Latin America, Pacific islands, Indian Ocean islands. ^c <i>Europe</i> : local transmission in northern Italy (2007) and southern France (2014) following importation of the virus.
Iatrogenic transmission	Transfusion-transmission confirmed; possibly renal transplantation.	One case of transfusion-transmitted infection declared by Brazilian authorities. ^d	Transfusion-transmission potentially possible.
Vertical infections	Yes. No congenital abnormalities reported.	Yes. Possible association with microcephaly and maculopathy.	Yes. Possible centro-facial hyperpigmentation.
Sexual transmission	Not reported.	Yes.	Not reported.
<i>Clinical features</i>			
Incubation period	3–10 days (usually 5–7 days).	2–12 days (usually 2–7 days).	2–6 days.
Duration of viraemia	2–3 days before to 4–5 days (range: 2–12 days) after onset of symptoms.	Usually 3–5 days after onset of symptoms (possibly over 11 days in some cases). Duration of viraemia prior to disease onset unknown.	About 6 days after onset of symptoms (range: 3–10) days.
Asymptomatic infection	14% in adults, 53% in children. Over 75% in some series.	80%.	3–37%.
Common clinical manifestations	Fever, headache, retro-orbital pain, maculopapular rash or "white islands in a sea of red", arthralgia, myalgia.	Fever, headache, conjunctivitis, itchy maculopapular rash, arthralgia (small joints of hands and feet), oedema of extremities, oral ulcers.	Fever, rash, myalgia, polyarthralgia, polyarthritis, diarrhoea, vomiting, abdominal pain.

(continued on next page)

Table 4 (continued)

	Dengue virus	Zika virus	Chikungunya virus
Uncommon or severe manifestations	Severe dengue: vascular leakage, haemoconcentration, bleeding diathesis, shock, end organ involvement (previously referred to as dengue haemorrhagic fever and dengue shock syndrome)	Guillain-Barré syndrome, encephalitis, meningoencephalitis. Possible congenital infection leading to microcephaly and maculopathy.	Conjunctivitis, uveitis, iridocyclitis, retinitis, meningoencephalitis, myocarditis, hepatitis, multi-organ failure.
Case-fatality ratio	Less than 1% to 5% with dengue fever. Severe dengue without adequate treatment, up to 20% or above, but can be reduced to less than 1% with proper management.	Very low.	0.1%.
Key laboratory findings	Leukopenia, lymphopenia, thrombocytopenia, elevated transaminases. Haemoconcentration (increased haematocrit) and coagulation abnormalities in severe dengue.	Relatively normal blood tests. Occasional mild thrombocytopenia, leukopenia with monocytosis reported.	Leukopenia, lymphopenia, thrombocytopenia, hypocalcaemia, elevated transaminases.
Diagnostic tests of choice	NS1 antigen detection, RT-PCR, antibody detection.	RT-PCR, antibody detection (ELISA and neutralization assay).	RT-PCR, antibody detection.
Antiviral therapy	None.	None.	None.
Vaccine prevention	Vaccine first marketed in 2015.	None.	None.

^a Updated map of countries with dengue transmission can be found at <http://www.healthmap.org/dengue/en/>.

^b Updated map of American countries with autochthonous Zika virus transmission during the 2015 outbreak can be found at Regional Office for the Americas of the World Health Organization, http://www.paho.org/hq/index.php?option=com_content&view=article&id=11669&Itemid=41716&lang=en.

^c Updated map of countries with chikungunya transmission can be found at <http://www.cdc.gov/chikungunya/geo/>.

^d Quoted by the Center for Infectious Disease Research and Policy, The University of Minnesota, on 4 February 2016. No official scientific publications are available at the time of writing. Available at: <http://www.cidrap.umn.edu/news-perspective/2016/02/brazil-confirms-blood-transfusion-zika-paho-calls-global-support>. [accessed 18.02.16.].

include the uncertainty of the risk of developing congenital abnormalities after infection of the pregnant women, the risk associated with infection at different time of gestation, and the lack of alternative antenatal diagnostics other than imaging studies. Current guidelines generally recommend monitoring of pregnant women with a recent travel history to endemic areas, early diagnosis of infection, close antenatal and postnatal surveillance and monitoring of infected women, exclusion of other congenital infections (such as toxoplasmosis, cytomegalovirus infection, rubella), amniocentesis for virological investigations if radiological abnormalities are detected, and consideration of termination of pregnancy after thorough counselling of the pregnant women.^{116,121,122} Zika virus can be detected by RT-PCR in the amniotic fluid of microcephalic fetuses, but the positive and negative predictive values of the RT-PCR finding (either in the amniotic fluid or even chorionic villus sampling) for the development of congenital abnormalities are unknown, and the test has not been well evaluated for specimens other than blood.^{93,116,122}

Zika virus can be cultured in a number cell lines such as Vero and LLC-MK2, or by intracerebral inoculation of

suckling mice.¹²³ While these are useful for virological studies and research, they are impractical for most clinical laboratories. Laboratory-acquired infections of Zika virus have also been reported.⁵⁰ Zika virus is classified as a biosafety level 2 organism according to the US CDC and human pathogen hazard group 3 according to the UK Advisory Committee on Dangerous Pathogens.^{124,125} Antibody detection and nucleic acid amplification using RT-PCR are the usual diagnostic tests of choice. A commercial system (EUROIMMUN AG, Lübeck, Germany) detecting anti-Zika IgG and IgM using ELISA (with recombinant NS1 antigen) and indirect immunofluorescence assay (which also allows differentiation between Zika, chikungunya, and dengue viruses) was marketed in January 2016. An in-house ELISA antibody test was developed during the Yap outbreak by the Centers for Disease Control and Prevention, USA. As expected, IgG and IgM antibody testing using ELISA shows cross-reaction with other flaviviruses, especially in patients with prior flaviviral infections. IgM antibodies are detectable from days 3–8 after onset of illness. Antibody testing by the plaque reduction neutralization test is more specific.⁴⁴ In-house indirect immunofluorescent assays have

also been described for antibody detection.¹²⁶ Although antibody testing suffers from cross reactivities with other flaviviruses, it remains an essential diagnostic means, especially in patients who presented late in the course of disease where RT-PCR tests could be negative (about 5–7 days after onset of disease).¹²⁶ The usual laboratory test of choice for acute Zika virus infections is RT-PCR on clinical samples, most commonly the peripheral blood. RT-PCR allows accurate differentiation of Zika virus from other pathogens which may share similar clinical manifestations, and this is especially useful in areas where co-circulation of different arboviruses is prevalent. Genotyping of the viral strains is also possible. In the Yap outbreak, one third of the sera collected within 10 days after disease onset were still positive by RT-PCR.⁵⁹ PCR protocols have been developed using primers directed towards various targets including E, NS5, and prM/E, and M.^{44,51,127–129} Duration of viraemia in humans ranges from 1 to more than 11 days after the onset of disease.⁵⁰ The viral load in patient sera appears to be relatively low, ranging from 930 to 728,800 (median: 21,495) copies/mL in a series of 17 patients in the Yap outbreak in 2007 (sera were mostly collected within 3 days after onset of disease).⁴⁴ One patient in that study had a viral load of 338,797 copies/mL when the blood was collected on day 11 after disease onset. Zika virus RNA has also been detected in the saliva, urine, and semen of some patients; remarkably, the positive rate of RT-PCR in saliva is higher than that of blood (57.1% vs. 28.1%).^{89,91,130} The additional value of performing RT-PCR on urine and saliva over blood, other than the ease of specimen collection, is unknown because the viral kinetics in these body fluids have not been determined.

The NS1 antigen of dengue virus has revolutionized the laboratory diagnosis of dengue, providing a simple and rapid point-of-care diagnostic means with high specificity and ability to diagnose the infection early in the course (especially in the first 3 days after disease onset).¹³¹ Although commercially available NS1-based diagnostic technique is currently limited to dengue, this may potentially be applicable to other flaviviral infections because circulating NS1 antigens have also been detected in Japanese encephalitis and West Nile virus infections.^{132,133} No information on the detection of circulating NS1 antigen in Zika virus infection is currently available. Caution should be exercised in the interpretation of dengue NS1 antigen testing results, for false positive result has been reported in a patient with acute Zika virus infection and other underlying diseases.^{134,135}

Treatment of Zika virus infection is primarily supportive. Nonsteroidal anti-inflammatory drugs should be avoided unless dengue has been excluded.^{116,122} Standard precautions in health care settings are adequate, with additional measures in mosquito-proofing of the health care facilities. Insect repellents and mosquito bite avoidance are recommended for health care workers looking after Zika patients.¹¹⁶ It would be prudent to recommend patients in the first one to two weeks after the onset of illness to adhere to bite avoidance measures in order to reduce the risk of secondary transmission. No antivirals are currently licensed for specific therapy against flaviviral infections (except hepatitis C virus), although *in vitro* studies with therapeutic antibodies, small interfering RNA, and

molecules against non-structural proteins (especially NS3 and NS5 proteins) are ongoing.^{136–138} A few currently available drugs such as the tetracyclines, chloroquine, amodiaquine, and mefenamic acid have shown *in vitro* inhibitory activities against flavivirus (mostly with dengue virus), but it is still too early to comment on their potential clinical benefits.^{139–144}

Prevention

Pregnant women are discouraged from travelling to Zika-endemic areas.¹⁴⁵ In addition to bite avoidance measures, non-pregnant, sexually active women of reproductive age residing in endemic areas should consider the issues of family planning and contraception, taking into account various social and religious precepts.¹²² At present, the only flaviviral vaccines available for human use are yellow fever (live attenuated), Japanese encephalitis (inactivated, live attenuated, and chimeric), tick-borne encephalitis (inactivated) vaccines, and the newly marketed dengue vaccine (live attenuated, recombinant, tetravalent; marketed since 2015). Claims were made by an Indian biotechnology company that two Zika virus vaccine candidates (recombinant and inactivated) can be tested soon; however, no details on the vaccine preparations are currently available in the scientific literature.¹⁴⁶ In any case, a normal vaccine development cycle usually requires years of preclinical and clinical studies and a Zika virus vaccine for human use is unlikely to be available in the near future.

In the absence of vaccines or chemoprophylaxis, the prevention of Zika virus infection follows the general rules for other vectorborne infections. Broadly speaking, this involves two major areas, personal protection through bite avoidance and vector control. Bite avoidance is equally important to both residents in and travellers to endemic areas. Personal protection includes general measures such as protective clothings, proper choice and use of insect repellents, and mosquito-proofing of houses. The use of insecticide-impregnated bednets has been one of the core elements in the prevention and control vectorborne diseases such as malaria in endemic countries. However, its role against the *Aedes* vectors of Zika virus depends on the behaviours of the vectors in specific geographical areas. In general, *Ae. aegypti* mosquitoes are endophilic (resting indoors), endophagous (biting indoors), anthropophilic (preferentially biting humans), and diurnal and crepuscular in their activities. *Ae. albopictus* mosquitoes are generally exophilic (resting outdoors), exophagous (biting indoors), and anthropophilic, and are aggressive daytime biters.^{147–149} However, it is known that the endophilic/exophilic and endophagous/exophagous behaviours are not absolute and these can be variable in different geographical areas.¹⁵⁰ A thorough knowledge of the local mosquitoes and their behaviours are therefore crucial to the control of vectorborne diseases, and this underlines the importance of long-term local vector surveillance.

The proper use of insect repellents is the keystone in personal protection against hematophagous arthropods. A number of insect repellents are widely available on the market, each of which has different repellent efficacies against different mosquito genera and other arthropods

such as mites, ticks, and flies. Despite negative publicity against it in recent years, N,N-diethyl-*m*-toluamide (DEET) remains the gold standard in insect repellents against which other newer compounds are benchmarked. DEET was initially developed and patented by the US Army in 1946 and commercialized since 1957. It is generally applied to skin in the form of liquids, aerosols, or lotions, and can be used to impregnate clothings if necessary (although permethrin is more commonly used for this purpose). Commercially available DEET formulations range from 4% to 100% in concentration. It is a common misconception that higher concentrations provide "more powerful" protection against arthropods. Higher concentrations merely prolong the duration of protection. At a concentration of 15%, DEET protects against *Ae. aegypti* and *Ae. albopictus* bites for about 7–8 hours.¹⁵¹ The effect plateaus at a concentration of about 50%. Although percutaneous absorption of DEET does occur, the level is extremely low as compared to the lethal doses observed in animals.^{152,153} DEET has an excellent record of safety and efficacy after 60 years of use. It is not oncogenic, teratogenic, or genotoxic at maximum tolerated doses in animals. Reports of serious human toxicity mainly relate to neurotoxicity, especially seizures in children. However, such reports remained rare (when compared to the total number of individuals exposed to DEET over the years) and in many of the reported cases, a definitive causal relationship between DEET and neurotoxicity cannot be established (other than the few cases of deliberate or accidental ingestion in huge quantities or improper use of the products).^{154–158} Similarly, although detectable levels of DEET can be found in cord blood of infants born to mothers using DEET during second and third trimesters of pregnancy, no adverse outcomes of pregnancy have been found in a double-blind, randomized trial.¹⁵⁹ Hence, when used appropriately according to recommendations, DEET is still considered to be safe in children older than 2–6 months of age, as well as in pregnant and lactating women.^{160–164} A DEET concentration of 20% to 30% is generally recommended for adult use.

Effective and safe alternatives to DEET are available. The most commonly used ones are ethyl butylacetylaminopropionate (IR3535, more effective against *Aedes* and *Culex* than *Anopheles* mosquitoes), picaridin (also known as icaridin; concentrations of $\geq 20\%$ are needed), *p*-menthane-3,8-diol (PMD), and possibly 2-undecanone (BioUD).^{151,165,166} For impregnation of clothings, shoes, and other equipment, permethrin is generally preferred.¹⁵⁸ Various botanical compounds have been advocated as natural and harmless insect repellents. These are often essential oils extracted from plants. While many of these oils do possess repellent activities, most of them are too volatile to offer lasting protections (usually lasting for less than 1 hour) and even these natural products may cause adverse reactions, especially skin irritation.^{158,165,167–169} Insect repellent-treated wristbands, garlic, oral vitamin B, and electronic buzzers (which claim to produce ultrasound to repel insects) are completely ineffective as bite avoidance measures.^{165,169} Whichever insect repellent is chosen, one must beware of potential limitations, such as repeating the application after heavy sweating, swimming, or raining, and applying the repellent about 20 minutes *after* the application of sunscreens. For international travellers,

preventive measures against other vectorborne infections should not be forgotten. These include the use of antimalarial chemoprophylaxis and yellow fever vaccination (as dictated by the destination) as appropriate, as there are overlaps in the current endemic areas of these infections and the possibility of further spread of Zika virus infection in the future.¹⁷⁰ Vaccination against Japanese encephalitis and tick-borne encephalitis may be considered for travellers to endemic areas with high-risk exposures, and dengue vaccination may potentially be considered in the future when more data are available.

Vector control is the only long-term solution to the control of vectorborne diseases. During outbreak situations, emergency measures such as the use of space spray (fogging) may be deployed to rapidly bring down the number of biting adults and terminate disease transmission. However, this is not a sustainable measure in the long run. The details of mosquito control are beyond the scope of this article. In brief, this mainly involves source reduction by larval control. *Ae. aegypti* and *Ae. albopictus* are typical container-breeding species which thrive in urban and man-made environments. Unlike other mosquitoes which breed in open water areas, environmental management measures are less likely to be effective. Raising the awareness of the community and engaging citizens in source reduction in households and their vicinity is the key to success in controlling these mosquito species.^{171,172} Other means of mosquito control, some of which are still experimental or in the early phases of field trials, include the use of biological measures such as entomopathogenic fungi and genetic measures including sterile insect techniques.^{172,173} Obviously, all vector control strategies have to be continued as perennial exercises because various mosquito genera, including *Aedes* spp., are capable of overwintering, and that the eggs of *Aedes* mosquitoes are well known for their ability to withstand prolonged periods of desiccation.^{174–176} Vector control measures must go hand in hand with vector surveillance, not only to monitor the density of mosquitoes (which may sometimes be correlated with the risk of transmission), but also to detect colonization by invasive species which may contribute to local spread of the infection.^{177–179} The public health significance of vector control and surveillance cannot be overstated. *Aedes* mosquitoes, in particular, *Ae. aegypti* and *Ae. albopictus*, are notorious for their vectorial capacity in transmitting multiple vectorborne infections. Dengue, for example, has taken its toll in many continents. From 4 January 2015 to 14 February 2016, 44,196 cases of dengue fever have been recorded in Taiwan, making it one of the biggest outbreaks of the disease on the island.¹⁸⁰ Given the fact that the competent vectors *Ae. aegypti* and *Ae. albopictus* are highly prevalent in many tropical and subtropical countries, the potential for Zika virus to cause outbreaks, and worse, co-circulation with other arboviruses, in these areas is very high.¹⁸¹

The role of border screening in preventing the importation of infectious diseases has previously been discussed.¹⁸² Although this is deployed in many countries (especially among Asian countries), border screening cannot reliably detect all infected individuals because of the asymptomatic incubation period. In the prevention of Zika virus infection, perhaps a more realistic approach is to

strengthen education of travellers prior to departure. This may involve travel medicine specialists in travel clinics as part of the pre-travel consultation, as well as reinforcing publicity and education in airports and other departure points. Of particular importance is a thorough pre-travel counselling of pregnant women intending to go to endemic areas for various arthropod-borne infections. This group of travellers may pose special difficulties in terms of vaccination, chemoprophylaxis, and choice of personal protection.¹⁸³ Exclusion of individuals with a recent history of travel to endemic areas from blood and organ donation would be a prudent precautionary measure. Given the risk of sexual transmission of Zika virus, abstinence or barrier contraceptives should be used by persons with recent visits to endemic areas and patients recovered from the illness. Nevertheless, because the longest duration of viraemia and viral shedding in other body fluids (such as semen, urine, and saliva) is presently unknown, the duration required for these precautions are at best tentative. For asymptomatic returned travellers, some authorities recommended that barrier contraception should be used for 28 days after returning, and for 6 months after recovery if symptomatic.^{121,184}

Conclusion

The geographical distribution of Zika virus has expanded tremendously since 2007. The threat of further expansion is real because of the constant increase in the volume of international travel, difficulties in controlling *Aedes* populations, invasion of *Aedes* species to more temperate countries, and global climate change which may increase the geographical extents favourable to the breeding of mosquitoes. Nucleic acid amplification remains the main diagnostic test of choice, though the availability of commercial antibody detection assays should complement laboratory diagnosis of the infection. Control measures currently relies on standard bite avoidance measures by residents and travellers alike, as well as integrated vector management in the community. The unique challenge of Zika virus infection lies not only on disease control, but the potential sequelae of congenital infection and severe neurological complications. Further studies may provide insights to the pathogenic mechanisms, earlier and more sensitive predictors of congenital abnormalities, and the possibilities of vaccination.

References

- World Health Organization. Global Strategy for Dengue Prevention and Control, 2012–2020. Available at: <http://www.who.int/denguecontrol/9789241504034/en/> [accessed 28.01.16].
- Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. *N Engl J Med* 2015;**372**:1231–9.
- Medlock JM, Hansford KM, Versteirt V, Cull B, Kampen H, Fontenille D, et al. An entomological review of invasive mosquitoes in Europe. *Bull Entomol Res* 2015;**105**:637–63.
- Kampen H, Werner D. Out of the bush: the Asian bush mosquito *Aedes japonicus japonicus* (Theobald, 1901) (Diptera, Culicidae) becomes invasive. *Parasit Vectors* 2014;**7**:59.
- Tomasello D, Schlagenhauf P. Chikungunya and dengue autochthonous cases in Europe, 2007–2012. *Travel Med Infect Dis* 2013;**11**:274–84.
- Kutsuna S, Kato Y, Moi ML, Kotaki A, Ota M, Shinohara K, et al. Autochthonous dengue fever, Tokyo, Japan, 2014. *Emerg Infect Dis* 2015;**21**:517–20.
- Reed W. Recent researches concerning the etiology, propagation, and prevention of yellow fever, by the United States Army Commission. *J Hyg (Lond)* 1902;**2**:101–19.
- Chaves-Carballo E. Carlos Finlay and yellow fever: triumph over adversity. *Mil Med* 2005;**170**:881–5.
- International Committee on Taxonomy of Viruses. Available at <http://www.ictvonline.org/virusTaxonomy.asp> [accessed 28.01.16].
- Lindenbach BD, Thiel HJ, Rice CM. Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. *Fields Virology*. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2007. p. 1102–52.
- Gubler DJ, Kuno G, Markoff L. Flaviviruses. In: Knipe DM, Howley PM, editors. *Fields Virology*. 5th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2007. p. 1154–252.
- Gaunt MW, Sall AA, de Lamballerie X, Falconar AK, Dzhanian TI, Gould EA. Phylogenetic relationships of flaviviruses correlate with their epidemiology, disease association and biogeography. *J Gen Virol* 2001;**82**:1867–76.
- Cook S, Holmes EC. A multigene analysis of the phylogenetic relationships among the flaviviruses (Family: *Flaviviridae*) and the evolution of vector transmission. *Arch Virol* 2006;**151**:309–25.
- Rodenhuis-Zybert IA, van der Schaar HM, da Silva Voorham JM, van der Ende-Metselaar H, Lei HY, Wilschut J, et al. Immature dengue virus: a veiled pathogen? *PLoS Pathog* 2010;**6**:e1000718.
- Muller DA, Young PR. The flavivirus NS1 protein: molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker. *Antiviral Res* 2013;**98**:192–208.
- Amorim JH, Alves RP, Boscardin SB, Ferreira LC. The dengue virus non-structural 1 protein: risks and benefits. *Virus Res* 2014;**181**:53–60.
- Crook KR, Miller-Kittrell M, Morrison CR, Scholle F. Modulation of innate immune signaling by the secreted form of the West Nile virus NS1 glycoprotein. *Virology* 2014;**458–459**:172–82.
- Melian EB, Edmonds JH, Nagasaki TK, Hinzman E, Floden N, Khromykh AA. West Nile virus NS2A protein facilitates virus-induced apoptosis independently of interferon response. *J Gen Virol* 2013;**94**:308–13.
- Liu WJ, Wang XJ, Clark DC, Lobigs M, Hall RA, Khromykh AA. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. *J Virol* 2006;**80**:2396–404.
- Duangchinda T, Dejnirattisai W, Vasanawathana S, Limpitikul W, Tangthawornchaikul N, Malasit P, et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. *Proc Natl Acad Sci U S A* 2010;**107**:16922–7.
- Kakumani PK, Rajgokul KS, Ponia SS, Kaur I, Mahanty S, Medigeshi GR, et al. Dengue NS3, an RNAi suppressor, modulates the human miRNA pathways through its interacting partner. *Biochem J* 2015;**471**:89–99.
- McLean JE, Wudzinska A, Datan E, Quagliano D, Zakeri Z. Flavivirus NS4A-induced autophagy protects cells against death and enhances virus replication. *J Biol Chem* 2011;**286**:22147–59.
- Dalrymple NA, Cimica V, Mackow ER. Dengue virus NS proteins inhibit RIG-I/MAVS signaling by blocking TBK1/IRF3 phosphorylation: dengue virus serotype 1 NS4A is a unique

- interferon-regulating virulence determinant. *MBio* 2015;6:e00553–15.
24. Zmurko J, Neyts J, Dallmeier K. Flaviviral NS4b, chameleon and jack-in-the-box roles in viral replication and pathogenesis, and a molecular target for antiviral intervention. *Rev Med Virol* 2015;25:205–23.
 25. Issur M, Geiss BJ, Bougie I, Picard-Jean F, Despains S, Mayette J, et al. The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure. *RNA* 2009;15:2340–50.
 26. Davidson AD. New insights into flavivirus nonstructural protein 5. *Adv Virus Res* 2009;74:41–101.
 27. Shi PY. Flavivirus NS5 prevents the InSTATement of IFN. *Cell Host Microbe* 2014;16:269–71.
 28. Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. *Trans R Soc Trop Med Hyg* 1952;46:509–20.
 29. MacNamara FN. Zika virus: a report on three cases of human infection during an epidemic of jaundice in Nigeria. *Trans R Soc Trop Med Hyg* 1954;48:139–45.
 30. Simpson DI. Zika virus infection in man. *Trans R Soc Trop Med Hyg* 1964;58:335–8.
 31. NCBI Nucleotide Database. <http://www.ncbi.nlm.nih.gov/nuccore>. [accessed 11.02.16].
 32. Wolfe MS, Calisher CH, McGuire K. Spondweni virus infection in a foreign resident of Upper Volta. *Lancet* 1982;2:1306–8.
 33. Sips GJ, Wilschut J, Smit JM. Neuroinvasive flavivirus infections. *Rev Med Virol* 2012;22:69–87.
 34. Nordin JD, Parker ED, Vazquez-Benitez G, Kharbanda EO, Naleway A, Marcy SM, Molitor B, Kuckler L, Baggs J. Safety of the yellow fever vaccine: a retrospective study. *J Travel Med* 2013;20:368–73.
 35. Kawano H, Rostapshov V, Rosen L, Lai CJ. Genetic determinants of dengue type 4 virus neurovirulence for mice. *J Virol* 1993;67:6567–75.
 36. Arroyo J, Guirakhoo F, Fenner S, Zhang ZX, Monath TP, Chambers TJ. Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). *J Virol* 2001;75:934–42.
 37. Zhang S, Li L, Woodson SE, Huang CY, Kinney RM, Barrett AD, Beasley DW. A mutation in the envelope protein fusion loop attenuates mouse neuroinvasiveness of the NY99 strain of West Nile virus. *Virology* 2006;353:35–40.
 38. Bordignon J, Strottmann DM, Mosimann AL, Probst CM, Stella V, Noronha L, Zanata SM, Dos Santos CN. Dengue neurovirulence in mice: identification of molecular signatures in the E and NS3 helicase domains. *J Med Virol* 2007;79:1506–17.
 39. Engel AR, Rumyantsev AA, Maximova OA, Speicher JM, Heiss B, Murphy BR, Pletnev AG. The neurovirulence and neuroinvasiveness of chimeric tick-borne encephalitis/dengue virus can be attenuated by introducing defined mutations into the envelope and NS5 protein genes and the 3' non-coding region of the genome. *Virology* 2010;405:243–52.
 40. Whiteman MC, Wicker JA, Kinney RM, Huang CY, Solomon T, Barrett AD. Multiple amino acid changes at the first glycosylation motif in NS1 protein of West Nile virus are necessary for complete attenuation for mouse neuroinvasiveness. *Vaccine* 2011;29:9702–10.
 41. Donadieu E, Bahuon C, Lowenski S, Zientara S, Couplier M, Lecollinet S. Differential virulence and pathogenesis of West Nile viruses. *Viruses* 2013;5:2856–80.
 42. Mlakar J, Korva M, Tul N, Popovič M, Poljšak-Prijatelj M, Mraz J, et al. Zika virus associated with microcephaly. *N Engl J Med* 2016 [In press].
 43. Kuno G, Chang GJ, Tsuchiya KR, Karabatsos N, Cropp CB. Phylogeny of the genus *Flavivirus*. *J Virol* 1998;72:73–83.
 44. Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ, et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. *Emerg Infect Dis* 2008;14:1232–9.
 45. Haddow AD, Schuh AJ, Yasuda CY, Kasper MR, Heang V, Huy R, et al. Genetic characterization of Zika virus strains: geographic expansion of the Asian lineage. *PLoS Negl Trop Dis* 2012;6:e1477.
 46. Faye O, Freire CC, Iamarino A, Faye O, de Oliveira JV, Diallo M, et al. Molecular evolution of Zika virus during its emergence in the 20th century. *PLoS Negl Trop Dis* 2014;8:e2636.
 47. Enfissi A, Codrington J, Roosblad J, Kazanji M, Rousset D. Zika virus genome from the Americas. *Lancet* 2016;387:227–8.
 48. Hamel R, Dejarnac O, Wichit S, Ekchariyawat P, Neyret A, Luplertlop N, et al. Biology of Zika virus infection in human skin cells. *J Virol* 2015;89:8880–96.
 49. Tappe D, Pérez-Girón JV, Zammarchi L, Rissland J, Ferreira DF, Jaenisch T, et al. Cytokine kinetics of Zika virus-infected patients from acute to reconvalescent phase. *Med Microbiol Immunol* 2015 [In press].
 50. Hayes EB. Zika virus outside Africa. *Emerg Infect Dis* 2009;15:1347–50.
 51. Buathong R, Hermann L, Thaisomboonsuk B, Rutvisuttinunt W, Klungthong C, Chinnawirotpisan P, et al. Detection of Zika virus infection in Thailand, 2012–2014. *Am J Trop Med Hyg* 2015;93:380–3.
 52. Alera MT, Hermann L, Tac-An IA, Klungthong C, Rutvisuttinunt W, Manasatienkij W, et al. Zika virus infection, Philippines, 2012. *Emerg Infect Dis* 2015;21:722–4.
 53. Olson JG, Ksiazek TG, Suhandiman, Triwibowo. Zika virus, a cause of fever in Central Java, Indonesia. *Trans R Soc Trop Med Hyg* 1981;75:389–93.
 54. Kwong JC, Druce JD, Leder K. Zika virus infection acquired during brief travel to Indonesia. *Am J Trop Med Hyg* 2013;89:516–7.
 55. Tappe D, Nachtigall S, Kapaun A, Schnitzler P, Günther S, Schmidt-Chanasit J. Acute Zika virus infection after travel to Malaysian Borneo, September 2014. *Emerg Infect Dis* 2015;21:911–3.
 56. Heang V, Yasuda CY, Sovann L, Haddow AD, Travassos da Rosa AP, Tesh RB, et al. Zika virus infection, Cambodia, 2010. *Emerg Infect Dis* 2012;18:349–51.
 57. Zammarchi L, Tappe D, Fortuna C, Remoli ME, Günther S, Venturi G, et al. Zika virus infection in a traveller returning to Europe from Brazil, March 2015. *Euro Surveill* 2015;20(23). pii: 21153.
 58. Kutsuna S, Kato Y, Takasaki T, Moi M, Kotaki A, Uemura H, et al. Two cases of Zika fever imported from French Polynesia to Japan, December 2013 to January 2014. *Euro Surveill* 2014;19(4). pii: 20683.
 59. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. *N Engl J Med* 2009;360:2536–43.
 60. Grard G, Caron M, Mombo IM, Nkoghe D, Mboui Ondo S, Jiolle D, et al. Zika virus in Gabon (Central Africa)—2007: a new threat from *Aedes albopictus*. *PLoS Negl Trop Dis* 2014;8:e2681.
 61. Roth A, Mercier A, Lepers C, Hoy D, Duituturaga S, Benyon E, et al. Concurrent outbreaks of dengue, chikungunya and Zika virus infections—an unprecedented epidemic wave of mosquito-borne viruses in the Pacific 2012–2014. *Euro Surveill* 2014;19(41). pii: 20929.
 62. Tognarelli J, Ulloa S, Villagra E, Lagos J, Aguayo C, Fasce R, et al. A report on the outbreak of Zika virus on Easter Island, South Pacific, 2014. *Arch Virol* 2015 [In press].
 63. Pan American Health Organization. Zika Epidemiological Alerts and Updates. Available at: <http://www.paho.org/hq/>

- index.php?option=com_content&view=article&id=11599&Itemid=41691&lang=en. [accessed 13.02.16].
64. Cao-Lormeau VM, Roche C, Teissier A, Robin E, Berry AL, Mallet HP, et al. Zika virus, French polynesia, South Pacific, 2013. *Emerg Infect Dis* 2014;**20**:1085–6.
 65. Zanutta C, de Melo VC, Mosimann AL, Dos Santos GI, Dos Santos CN, Luz K. First report of autochthonous transmission of Zika virus in Brazil. *Mem Inst Oswaldo Cruz* 2015;**110**: 569–72.
 66. World Health Organization. Zika situation report, 5 February 2016. Available at: http://apps.who.int/iris/bitstream/10665/204348/1/zikasitrep_5Feb2016_eng.pdf?ua=1. [accessed on 13.02.16.].
 67. Centers for Disease Control and Prevention. Zika virus disease in the United States, 2015–2016. Available at: <http://www.cdc.gov/zika/geo/united-states.html>. [accessed 13.02.16].
 68. World Health Organization. Zika virus infection – Region of the Americas. Disease Outbreak News. 8 February 2016. Available at: <http://www.who.int/csr/don/8-february-2016-zika-americas-region/en/>. [accessed 13.02.16].
 69. Pan American Health Organization. Cumulative Zika confirmed and suspected cases reported by countries and territories in the Americas, 2015–2016. Updated as of February 12, 2016. Available at: http://ais.paho.org/phis/viz/ed_zika_cases.asp. [accessed 13.02.16.].
 70. McCrae AW, Kirya BG. Yellow fever and Zika virus epizootics and enzootics in Uganda. *Trans R Soc Trop Med Hyg* 1982;**76**: 552–62.
 71. Maciel-de-Freitas R, Codeço CT, Lourenço-de-Oliveira R. Daily survival rates and dispersal of *Aedes aegypti* females in Rio de Janeiro, Brazil. *Am J Trop Med Hyg* 2007;**76**:659–65.
 72. Goindin D, Delannay C, Ramdini C, Gustave J, Fouque F. Parity and longevity of *Aedes aegypti* according to temperatures in controlled conditions and consequences on dengue transmission risks. *PLoS One* 2015;**10**:e0135489.
 73. Boorman JP, Porterfield JS. A simple technique for infection of mosquitoes with viruses; transmission of Zika virus. *Trans R Soc Trop Med Hyg* 1956;**50**:238–42.
 74. Haddow AJ, Williams MC, Woodall JP, Simpson DIH, Goma LKH. Twelve isolations of Zika virus from *Aedes (Stegomyia) africanus* (Theobald) taken in and above a Uganda forest. *Bull World Health Organ* 1964;**31**:57–69.
 75. Savage HM, Ledermann JP, Yug L, Burkhalter KL, Marfel M, Hancock WT. Incrimination of *Aedes (Stegomyia) hensilli* Farner as an epidemic vector of Chikungunya virus on Yap Island, Federated States of Micronesia, 2013. *Am J Trop Med Hyg* 2015;**92**:429–36.
 76. Savage HM, Fritz CL, Rutstein D, Yolwa A, Vorndam V, Gubler DJ. Epidemic of dengue-4 virus in Yap State, Federated States of Micronesia, and implication of *Aedes hensilli* as an epidemic vector. *Am J Trop Med Hyg* 1998;**58**: 519–24.
 77. Ledermann JP, Guillaumot L, Yug L, Saweyog SC, Tided M, Machieng P, et al. *Aedes hensilli* as a potential vector of Chikungunya and Zika viruses. *PLoS Negl Trop Dis* 2014;**8**: e3188.
 78. Wong PS, Li MZ, Chong CS, Ng LC, Tan CH. *Aedes (Stegomyia) albopictus* (Skuse): a potential vector of Zika virus in Singapore. *PLoS Negl Trop Dis* 2013;**7**:e2348.
 79. Berthet N, Nakouné E, Kamgang B, Selekon B, Descorps-Declère S, Gessain A, et al. Molecular characterization of three Zika flaviviruses obtained from sylvatic mosquitoes in the Central African Republic. *Vector Borne Zoonotic Dis* 2014;**14**:862–5.
 80. Reinert JF, Harbach RE, Kitching IJ. Phylogeny and classification of tribe Aedini (Diptera: Culicidae). *Zool J Linn Soc* 2009;**157**:700–94.
 81. Kraemer MU, Sinka ME, Duda KA, Mylne AQ, Shearer FM, Barker CM, et al. The global distribution of the arbovirus vectors *Aedes aegypti* and *Ae. albopictus*. *Elife* 2015;**4**:e08347.
 82. European Centre for Disease Prevention and Control. Rapid risk assessment. Zika virus infection outbreak, French Polynesia, 14 February 2014. Available at: <http://ecdc.europa.eu/en/publications/Publications/Zika-virus-French-Polynesia-rapid-risk-assessment.pdf>. [accessed 13.02.16.].
 83. Musso D, Nilles EJ, Cao-Lormeau VM. Rapid spread of emerging Zika virus in the Pacific area. *Clin Microbiol Infect* 2014;**20**:O595–6.
 84. Marcondes CB, Ximenes MF. Zika virus in Brazil and the danger of infestation by *Aedes (Stegomyia)* mosquitoes. *Rev Soc Bras Med Trop* 2015 [In press].
 85. Brady OJ, Godfray HC, Tatem AJ, Gething PW, Cohen JM, McKenzie FE, et al. Vectorial capacity and vector control: reconsidering sensitivity to parameters for malaria elimination. *Trans R Soc Trop Med Hyg* 2016;**110**:107–17.
 86. Kramer LD, Ciota AT. Dissecting vectorial capacity for mosquito-borne viruses. *Curr Opin Virol* 2015;**15**:112–8.
 87. Diagne CT, Diallo D, Faye O, Ba Y, Faye O, Gaye A, et al. Potential of selected Senegalese *Aedes* spp. mosquitoes (Diptera: Culicidae) to transmit Zika virus. *BMC Infect Dis* 2015;**15**:492.
 88. Leung GH, Baird RW, Druce J, Anstey NM. Zika virus infection in Australia following a monkey bite in Indonesia. *Southeast Asian J Trop Med Public Health* 2015;**46**:460–4.
 89. Musso D, Roche C, Nhan TX, Robin E, Teissier A, Cao-Lormeau VM. Detection of Zika virus in saliva. *J Clin Virol* 2015;**68**:53–5.
 90. Foy BD, Kobylinski KC, Chilson Foy JL, Blitvich BJ, Travassos da Rosa A, Haddow AD, Lanciotti RS, Tesh RB. Probable non-vector-borne transmission of Zika virus, Colorado, USA. *Emerg Infect Dis* 2011;**17**:880–2.
 91. Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau VM. Potential sexual transmission of Zika virus. *Emerg Infect Dis* 2015;**21**:359–61. Erratum in *Emerg Infect Dis* 2015;**21**:552.
 92. Atkinson B, Hearn P, Afrough B, Lumley S, Carter D, Aarons EJ, et al. Detection of Zika virus in semen. *Emerg Infect Dis* 2016 [In press].
 93. Besnard M, Lastere S, Teissier A, Cao-Lormeau V, Musso D. Evidence of perinatal transmission of Zika virus, French Polynesia, December 2013 and February 2014. *Euro Surveill* 2014;**19**(13). pii: 20751.
 94. Endy TP, Anderson KB, Nisalak A, Yoon IK, Green S, Rothman AL, Thomas SJ, Jarman RG, Libraty DH, Gibbons RV. Determinants of inapparent and symptomatic dengue infection in a prospective study of primary school children in Kamphaeng Phet, Thailand. *PLoS Negl Trop Dis* 2011;**5**:e975.
 95. World Health Organization. Japanese encephalitis vaccines: WHO position paper—February 2015. *Wkly Epidemiol Rec* 2015;**90**:69–87.
 96. Monath TP, Vasconcelos PFC. Yellow fever. *J Clin Virol* 2015;**64**:160–73.
 97. Stramer SL, Linnen JM, Carrick JM, Foster GA, Krysztof DE, Zou S, et al. Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. *Transfusion* 2012;**52**: 1657–66.
 98. Centers for Disease Control and Prevention (CDC). West Nile virus transmission via organ transplantation and blood transfusion—Louisiana, 2008. *MMWR Morb Mortal Wkly Rep* 2009;**58**:1263–7.
 99. Montgomery SP, Brown JA, Kuehnert M, Smith TL, Crall N, Lanciotti RS, et al. 2003 West Nile Virus Transfusion-Associated Transmission Investigation Team. Transfusion-

- associated transmission of West Nile virus, United States 2003 through 2005. *Transfusion* 2006;**46**:2038–46.
100. Leiby DA, Gill JE. Transfusion-transmitted tick-borne infections: a cornucopia of threats. *Transfus Med Rev* 2004;**18**: 293–306.
 101. Petersen LR, Busch MP. Transfusion-transmitted arboviruses. *Vox Sang* 2010;**98**:495–503.
 102. Liunbruno GM, Calteri D, Petropulacos K, Mattivi A, Po C, Macini P, et al. The chikungunya epidemic in Italy and its repercussion on the blood system. *Blood Transfus* 2008;**6**: 199–210.
 103. Brouard C, Bernillon P, Quatresous I, Pilonel J, Assal A, de Valk H, et al. workgroup “Quantitative Estimation of the Risk of Blood Donation Contamination by Infectious Agents”. Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007. *Transfusion* 2008;**48**:1333–41.
 104. Musso D, Nhan T, Robin E, Roche C, Bierlaire D, Zisou K, et al. Potential for Zika virus transmission through blood transfusion demonstrated during an outbreak in French Polynesia, November 2013 to February 2014. *Euro Surveill* 2014;**19**(14). pii: 20761.
 105. Ios S, Mallet HP, Leparc Goffart I, Gauthier V, Cardoso T, Herida M. Current Zika virus epidemiology and recent epidemics. *Med Mal Infect* 2014;**44**:302–7.
 106. Vasilakis N, Cardoso J, Hanley KA, Holmes EC, Weaver SC. Fever from the forest: prospects for the continued emergence of sylvatic dengue virus and its impact on public health. *Nat Rev Microbiol* 2011;**9**:532–41.
 107. Gubler DJ, Suharyono W, Tan R, Abidin M, Sie A. Viraemia in patients with naturally acquired dengue infection. *Bull World Health Organ* 1981;**59**:623–30.
 108. Tomaszek KM, Margolis HS. Dengue: a potential transfusion-transmitted disease. *Transfusion* 2011;**51**:1654–60.
 109. Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT. Chikungunya: a re-emerging virus. *Lancet* 2012;**379**:662–71.
 110. Villamil-Gómez W, Alba-Silvera L, Menco-Ramos A, Gonzalez-Vergara A, Molinares-Palacios T, Barrios-Corales M, et al. Congenital chikungunya virus infection in Sincelejo, Colombia: a case series. *J Trop Pediatr* 2015;**61**:386–92.
 111. Vasani R, Kanhere S, Chaudhari K, Phadke V, Mukherjee P, Gupta S, Kasliwal C, Poojary S. Congenital chikungunya—a cause of neonatal hyperpigmentation. *Pediatr Dermatol* 2015 [In press].
 112. Win MK, Chow A, Dimatatac F, Go CJ, Leo YS. Chikungunya fever in Singapore: acute clinical and laboratory features, and factors associated with persistent arthralgia. *J Clin Virol* 2010;**49**:111–4.
 113. Sissoko D, Ezzedine K, Moendandzé A, Giry C, Renault P, Malvy D. Field evaluation of clinical features during chikungunya outbreak in Mayotte, 2005–2006. *Trop Med Int Health* 2010;**15**:600–7.
 114. Borgherini G, Poubeau P, Staikowsky F, Lory M, Le Moullec N, Becquart JP, Wengling C, Michault A, Paganin F. Outbreak of chikungunya on Reunion Island: early clinical and laboratory features in 157 adult patients. *Clin Infect Dis* 2007;**44**:1401–7.
 115. Oehler E, Watrin L, Larre P, Leparc-Goffart I, Lasterre S, Valour F, et al. Zika virus infection complicated by Guillain-Barre syndrome—case report, French Polynesia, December 2013. *Euro Surveill* 2014;**19**(9). pii: 20720.
 116. Pan American Health Organization/World Health Organization. Epidemiological Alert. Neurological syndrome, congenital malformations, and Zika virus infection. Implications for public health in the Americas. 1 December 2015. Available at: http://www.paho.org/hq/index.php?option=com_docman&task=doc_view&Itemid=270&gid=32405&lang=en. [accessed 13.02.16.].
 117. Dupont-Rouzeyrol M, O’Connor O, Calvez E, Daurès M, John M, Grangeon JP, Gourinat AC. Co-infection with Zika and dengue viruses in 2 patients, New Caledonia, 2014. *Emerg Infect Dis* 2015;**21**:381–2.
 118. Ventura CV, Maia M, Bravo-Filho V, Góis AL, Belfort Jr R. Zika virus in Brazil and macular atrophy in a child with microcephaly. *Lancet* 2016;**387**:228.
 119. Oliveira Melo AS, Malinger G, Ximenes R, Szejnfeld PO, Alves Sampaio S, Bispo de Filippis AM. Zika virus intrauterine infection causes fetal brain abnormality and microcephaly: tip of the iceberg? *Ultrasound Obstet Gynecol* 2016;**47**:6–7.
 120. Ventura CV, Maia M, Ventura BV, Linden VV, Araújo EB, Ramos CV, et al. Ophthalmological findings in infants with microcephaly and presumable intra-uterus Zika virus infection. *Arq Bras Oftalmol* 2016;**79**:1–3.
 121. Royal College of Obstetricians and Gynaecologists. Interim clinical guidelines on Zika virus infection and pregnancy. 5 February 2016. Available at: <https://www.rcog.org.uk/globalassets/documents/news/zika-virus-interim-guidelines.pdf>. [accessed 13.02.16.].
 122. Oduyebo T, Petersen EE, Rasmussen SA, Mead PS, Meaney-Delman D, Renquist CM, et al. Update: Interim guidelines for health care providers caring for pregnant women and women of reproductive age with possible Zika virus exposure—United States, 2016. *MMWR Morb Mortal Wkly Rep* 2016;**65**:122–7.
 123. Way JH, Bowen ET, Platt GS. Comparative studies of some African arboviruses in cell culture and in mice. *J Gen Virol* 1976;**30**:123–30.
 124. Centers for Disease Control and Prevention. *Biosafety in Microbiological and Biomedical Laboratories*. 5th edition 2009 Available at: <http://www.cdc.gov/biosafety/publications/bmbl5/bmbl.pdf> [accessed 13.02.16.].
 125. Advisory Committee on Dangerous Pathogens, UK. *The Approved List of Biological Agents*. 2013. Available at: <http://www.hse.gov.uk/pubns/misc208.pdf> [accessed on 13.02.16.].
 126. Tappe D, Rissland J, Gabriel M, Emmerich P, Gunther S, Held G, et al. First case of laboratory-confirmed Zika virus infection imported into Europe, November 2013. *Euro Surveill* 2014 Jan 30;**19**(4). pii: 20685.
 127. Faye O, Faye O, Dupressoir A, Weidmann M, Ndiaye M. Alpha Sall A. One-step RT-PCR for detection of Zika virus. *J Clin Virol* 2008;**43**:96–101.
 128. Faye O, Faye O, Diallo D, Diallo M, Weidmann M, Sall AA. Quantitative real-time PCR detection of Zika virus and evaluation with field-caught mosquitoes. *Virol J* 2013;**10**:311.
 129. Balm MN, Lee CK, Lee HK, Chiu L, Koay ES, Tang JW. A diagnostic polymerase chain reaction assay for Zika virus. *J Med Virol* 2012;**84**:1501–5.
 130. Shinohara K, Kutsuna S, Takasaki T, Moi ML, Ikeda M, Kotaki A, Yamamoto K, Fujiya Y, Mawatari M, Takeshita N, Hayakawa K, Kanagawa S, Kato Y, Ohmagari N. Zika fever imported from Thailand to Japan, and diagnosed by PCR in the urines. *J Travel Med* 2016;**23**. pii: tav011.
 131. Ratnam I, Leder K, Black J, Torresi J. Dengue fever and international travel. *J Travel Med* 2013;**20**:384–93.
 132. Kumar JS, Parida M, Rao PV. Monoclonal antibody-based antigen capture immunoassay for detection of circulating non-structural protein NS1: implications for early diagnosis of Japanese encephalitis virus infection. *J Med Virol* 2011;**83**: 1063–70.
 133. Saxena D, Kumar JS, Parida M, Sivakumar RR, Patro IK. Development and evaluation of NS1 specific monoclonal antibody based antigen capture ELISA and its implications in clinical diagnosis of West Nile virus infection. *J Clin Virol* 2013;**58**:528–34.
 134. Gyurech D, Schilling J, Schmidt-Chanasit J, Cassinotti P, Kaepfeli F, Dobec M. False positive dengue NS1 antigen test in

- a traveller with an acute Zika virus infection imported into Switzerland. *Swiss Med Wkly* 2016;146:w14296.
135. Chung SJ, Krishnan PU, Leo YS. Two cases of false-positive dengue non-structural protein 1 (NS1) antigen in patients with hematological malignancies and a review of the literature on the use of NS1 for the detection of dengue infection. *Am J Trop Med Hyg* 2015;92:367–9.
 136. Fibriansah G, Lok SM. The development of therapeutic antibodies against dengue virus. *Antiviral Res* 2016 [In press].
 137. Idrees S, Ashfaq UA. RNAi: antiviral therapy against dengue virus. *Asian Pac J Trop Biomed* 2013;3:232–6.
 138. Bollati M, Alvarez K, Assenberg R, Baronti C, Canard B, Cook S, et al. Structure and functionality in flavivirus NS-proteins: perspectives for drug design. *Antiviral Res* 2010;87:125–48.
 139. Rothan HA, Mohamed Z, Paydar M, Rahman NA, Yusof R. Inhibitory effect of doxycycline against dengue virus replication *in vitro*. *Arch Virol* 2014;159:711–8.
 140. Rothan HA, Buckle MJ, Ammar YA, Mohammadjavad P, Shatrah O, Noorsaadah AR, et al. Study the antiviral activity of some derivatives of tetracycline and non-steroid anti-inflammatory drugs towards dengue virus. *Trop Biomed* 2013;30:681–90.
 141. Farias KJ, Machado PR, de Almeida Junior RF, de Aquino AA, da Fonseca BA. Chloroquine interferes with dengue-2 virus replication in U937 cells. *Microbiol Immunol* 2014;58:318–26.
 142. Farias KJ, Machado PR, da Fonseca BA. Chloroquine inhibits dengue virus type 2 replication in Vero cells but not in C6/36 cells. *ScientificWorldJournal* 2013;2013:282734.
 143. Farias KJ, Machado PR, Muniz JA, Imbeloni AA, da Fonseca BA. Antiviral activity of chloroquine against dengue virus type 2 replication in *Aotus* monkeys. *Viral Immunol* 2015;28:161–9.
 144. Boonyasuppayakorn S, Reichert ED, Manzano M, Nagarajan K, Padmanabhan R. Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity. *Antiviral Res* 2014;106:125–34.
 145. TravelHealthPro, National Travel Health Network and Centre. Zika virus – update and advice for travellers including pregnant women. Available at: <http://travelhealthpro.org.uk/zika-virus-update-and-advice-for-travellers-including-pregnant-women/>. [accessed 13.02.16.].
 146. ScienceAlert. An Indian company says they have two Zika vaccine candidates ready for pre-clinical trials. Available at: <http://www.sciencealert.com/an-indian-company-says-they-have-2-zika-vaccines-ready-for-pre-clinical-trials>. [accessed 13.02.16.].
 147. Delatte H, Desvars A, Bouétard A, Bord S, Gimonneau G, Vourc'h G, Fontenille D. Blood-feeding behavior of *Aedes albopictus*, a vector of Chikungunya on La Réunion. *Vector Borne Zoonotic Dis* 2010;10:249–58.
 148. Bonizzoni M, Gasperi G, Chen X, James AA. The invasive mosquito species *Aedes albopictus*: current knowledge and future perspectives. *Trends Parasitol* 2013;29:460–8.
 149. Higa Y. Dengue vectors and their spatial distribution. *Trop Med Health* 2011;39(4 Suppl):17–27.
 150. Mukwaya LG. Host preference in *Aedes (Stegomyia)* mosquitoes in Uganda. II. Studies on indoor and outdoor biting and resting behaviour with special reference to *Aedes aegypti* L. *Acta Trop* 1974;31:165–76.
 151. Lupi E, Hatz C, Schlagenhauf P. The efficacy of repellents against *Aedes*, *Anopheles*, *Culex* and *Ixodes* spp. — a literature review. *Travel Med Infect Dis* 2013;11:374–411.
 152. Sudakin DL, Osimitz T. DEET. In: Krieger R, editor. *Hayes' Handbook of Pesticide Toxicology*. 3rd ed. London, UK: Academic Press; 2010. p. 2111–25.
 153. Selim S, Hartnagel Jr RE, Osimitz TG, Gabriel KL, Schoenig GP. Absorption, metabolism, and excretion of N,N-diethyl-m-toluamide following dermal application to human volunteers. *Fundam Appl Toxicol* 1995;25:95–100.
 154. Tenenbein M. Severe toxic reactions and death following the ingestion of diethyltoluamide-containing insect repellents. *JAMA* 1987;258:1509–11.
 155. Wiles D, Yee J, Castillo U, Russell J, Spiller H, Casavant M. A lethal case of DEET toxicity due to intentional ingestion. *J Anal Toxicol* 2014;38:696–8.
 156. Osimitz TG, Murphy JV, Fell LA, Page B. Adverse events associated with the use of insect repellents containing N,N-diethyl-m-toluamide (DEET). *Regul Toxicol Pharmacol* 2010;56:93–9.
 157. Briassoulis G, Narlioglou M, Hatzis T. Toxic encephalopathy associated with use of DEET insect repellents: a case analysis of its toxicity in children. *Hum Exp Toxicol* 2001;20:8–14.
 158. Katz TM, Miller JH, Hebert AA. Insect repellents: historical perspectives and new developments. *J Am Acad Dermatol* 2008;58:865–71.
 159. McGready R, Hamilton KA, Simpson JA, Cho T, Luxemburger C, Edwards R, et al. Safety of the insect repellent N,N-diethyl-m-toluamide (DEET) in pregnancy. *Am J Trop Med Hyg* 2001;65:285–9.
 160. Public Health England. Guidelines for malaria prevention in travellers from the UK 2015. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/461295/2015.09.16_ACMP_guidelines_FINAL.pdf. [accessed 09.02.16.].
 161. Onyett H; Canadian Paediatric Society Infectious Diseases and Immunization Committee. Preventing mosquito and tick bites: a Canadian update. *Paediatr Child Health* 2014;19:326–8.
 162. Nasci RS, Wirtz RA, Brogdon WG. Protection against mosquitoes, ticks, and other arthropods. The pre-travel consultation: counseling and advice for travelers. In: *CDC Health Information for International Travel*; 2016. Available at: <http://www.wnc.cdc.gov/travel/yellowbook/2016/the-pre-travel-consultation/protection-against-mosquitoes-ticks-other-arthropods> [accessed 09.02.16.].
 163. Antwi FB, Shama LM, Peterson RK. Risk assessments for the insect repellents DEET and picaridin. *Regul Toxicol Pharmacol* 2008;51:31–6.
 164. Koren G, Matsui D, Bailey B. DEET-based insect repellents: safety implications for children and pregnant and lactating women. *CMAJ* 2003;169:209–12.
 165. Goodyer LI, Croft AM, Frances SP, Hill N, Moore SJ, Onyango SP, Debboun M. Expert review of the evidence base for arthropod bite avoidance. *J Travel Med* 2010;17:182–92.
 166. Witting-Bissinger BE, Stumpf CF, Donohue KV, Apperson CS, Roe RM. Novel arthropod repellent, BioUD, is an efficacious alternative to DEET. *J Med Entomol* 2008;45:891–8.
 167. Trongtokit Y, Rongsriyam Y, Komalamisra N, Apiwathnasorn C. Comparative repellency of 38 essential oils against mosquito bites. *Phytother Res* 2005;19:303–9.
 168. Amer A, Mehlhorn H. Repellency effect of forty-one essential oils against *Aedes*, *Anopheles*, and *Culex* mosquitoes. *Parasitol Res* 2006;99:478–90.
 169. PPAV Working Groups. Personal protection against biting insects and ticks. *Parasite* 2011;18:93–111.
 170. World Health Organization. Yellow fever vaccination requirements and recommendations; malaria situation; and other vaccination requirements. Available at: http://www.who.int/ith/ITH_country_list.pdf. [accessed on 11.2.16.].
 171. Chang SC. Raising clinical awareness for better dengue fever outbreak control. *J Formos Med Assoc* 2015;114:1025–6.
 172. Baldacchino F, Caputo B, Chandre F, Drago A, della Torre A, Montarsi F, et al. Control methods against invasive *Aedes* mosquitoes in Europe: a review. *Pest Manag Sci* 2015;71:1471–85.
 173. Carvalho DO, McKemey AR, Garziera L, Lacroix R, Donnelly CA, Alphey L, et al. Suppression of a field population

- of *Aedes aegypti* in Brazil by sustained release of transgenic male mosquitoes. *PLoS Negl Trop Dis* 2015;9:e0003864.
174. Mogi M. Overwintering strategies of mosquitoes (Diptera: *Culicidae*) on warmer islands may predict impact of global warming on Kyushu, Japan. *J Med Entomol* 1996;33:438–44.
 175. Takumi K, Scholte EJ, Braks M, Reusken C, Avenell D, Medlock JM. Introduction, scenarios for establishment and seasonal activity of *Aedes albopictus* in The Netherlands. *Vector Borne Zoonotic Dis* 2009;9:191–6.
 176. Faull KJ, Williams CR. Intraspecific variation in desiccation survival time of *Aedes aegypti* (L.) mosquito eggs of Australian origin. *J Vector Ecol* 2015;40:292–300.
 177. Sanchez L, Vanlerberghe V, Alfonso L, Marquetti Mdel C, Guzman MG, Bisset J, et al. *Aedes aegypti* larval indices and risk for dengue epidemics. *Emerg Infect Dis* 2006;12:800–6.
 178. Kim Lien PT, Duoc VT, Gavotte L, Cornillot E, Nga PT, Briant L, et al. Role of *Aedes aegypti* and *Aedes albopictus* during the 2011 dengue fever epidemics in Hanoi, Vietnam. *Asian Pac J Trop Med* 2015;8:543–8.
 179. Bowman LR, Runge-Ranzinger S, McCall PJ. Assessing the relationship between vector indices and dengue transmission: a systematic review of the evidence. *PLoS Negl Trop Dis* 2014;8:e2848.
 180. Taiwan National Infectious Disease Statistics System. Statistics for dengue fever, nationwide, indigenous and imported, by date of onset. Available at: <http://nidss.cdc.gov.tw/en/SingleDisease.aspx?dc=1&dt=2&disease=061>. [accessed 18.2.16.].
 181. Chen TH, Jian SW, Wang CY, Lin C, Wang PF, Su CL, et al. Susceptibility of *Aedes albopictus* and *Aedes aegypti* to three imported Chikungunya virus strains, including the E1/226V variant in Taiwan. *J Formos Med Assoc* 2015;114:546–52.
 182. Wong SS, Wong SC. Ebola virus disease in nonendemic countries. *J Formos Med Assoc* 2015;114:384–98.
 183. Carroll ID, Williams DC. Pre-travel vaccination and medical prophylaxis in the pregnant traveler. *Travel Med Infect Dis* 2008;6:259–75.
 184. Oster AM, Brooks JT, Stryker JE, Kachur RE, Mead P, Pesik NT, et al. Interim guidelines for prevention of sexual transmission of Zika virus—United States, 2016. *MMWR Morb Mortal Wkly Rep* 2016;65:120–1.